Background {#Sec1}
==========

The Association of Southeast Asian Nations (ASEAN) region consists of ten countries -- Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam -- and is home to over half a billion people. The burden of cancer is increasing in the ASEAN region, due to population ageing and growth and the adoption of cancer-associated lifestyle behaviours \[[@CR1]\]. In 2012, there were estimated to be over 750,000 new cases of cancer, and incidence is expected to rise to 1.3 million per year by 2030 \[[@CR2]\]. Survival rates for most cancers are poor and quality of life is greatly impaired \[[@CR2]--[@CR4]\]. In addition to this significant disease burden, cancer can have a profound economic effect on individuals and their households, especially among the poor and under-insured \[[@CR5]\].

Most studies examining the economic burden of cancer have, however, been conducted in high-income settings. Little is known about its economic impact in low- and middle-income settings, where the financial implication of a cancer diagnosis may not be equitable because out-of-pocket (OOP) payments are the principal means of financing health care \[[@CR6]\]. This not only relates to primary treatment, but may include long-term costs of adjuvant therapy and follow-up care \[[@CR7]--[@CR9]\]. Hence, a cancer diagnosis can quickly result in catastrophic payments for a household; that is, spending a disproportionate amount of household income on cancer treatment \[[@CR10]\]. Furthermore, patients may be unable to continue working due to the burden of their symptoms, treatment, or side-effects, leading to poorer economic circumstances \[[@CR11]\].

Health insurance is seen as an important means in offering households protection from catastrophic payments for illness. However, the extent of financial protection through insurance depends on which health services are covered and the level of subsidy offered. In the ASEAN region, while population coverage varies between 8 % (Laos) and 100 % (Malaysia), all countries -- including those with universal health coverage -- rely heavily on OOP financing \[[@CR12], [@CR13]\].

Despite the risk of a cancer epidemic overwhelming the region, governments have been slow to react to the health consequences of socioeconomic and demographic changes. Hence, in 2011, two regional initiatives were launched to increase cancer awareness and inform priority setting. First, a series of roundtable meetings of key stakeholders and experts were organised to generate knowledge and interest through engagement with the media \[[@CR14], [@CR15]\]. Second, a study of new cancer patients in eight countries in the ASEAN region (Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand, and Vietnam) was instigated -- the Asean CosTs In ONcology (ACTION) study -- to assess the economic and health impact of cancer. This paper presents the main results.

Methods {#Sec2}
=======

Ethical approval {#Sec3}
----------------

The ACTION study was approved by the University of Sydney's Human Research Ethics Committee. Approvals from local institutional ethics committees and other regional or national regulatory bodies were obtained prior to the initiation of the study in all centres (Additional file [1](#MOESM1){ref-type="media"}). Written informed consent, complying with local, regional, and national requirements, was obtained from all participants prior to entry into the study.

Study design {#Sec4}
------------

ACTION was a prospective longitudinal study; detailed methods have been published previously \[[@CR16]\]. In brief, patients diagnosed with a first time cancer were consecutively recruited (within 12 weeks from initial date of diagnosis) from 47 sites, including public and private hospitals and cancer centres. Patients were aged 18 years and older, aware of their cancer diagnosis, and willing to participate in follow-up interviews. Participants were interviewed (face-to-face or by telephone) at baseline, 3, and 12 months after diagnosis. Questionnaires were translated into local languages.

Baseline measures and key outcomes {#Sec5}
----------------------------------

Data were collected on age, sex, marital status, country of residence, highest level of education attained, employment status, recent experience of economic hardship (whether in the previous 12 months they were unable to make any necessary household payments (for example, food, housing) or needed assistance to do so) \[[@CR17]\], annual household income, and health insurance status. Clinical characteristics, cancer site, and cancer stage (TNM classification) were obtained from medical records. Health-related quality of life was assessed using the EuroQol (EQ-5D) \[[@CR18]\]. Further details are given in the study protocol \[[@CR16]\].

The primary outcome at 12 months was financial catastrophe (FC) following treatment for cancer, defined as OOP costs at 12 months equal to or exceeding 30 % of annual household income \[[@CR19], [@CR20]\]. OOP costs represented hospital and non-hospital health care costs which were directly incurred by patients at point of delivery and not reimbursed by insurance. Participants prospectively completed a cost diary for the duration of the study. The second key outcome was all-cause mortality. FC and death were recorded at both follow-up interviews.

Statistical analyses {#Sec6}
--------------------

Multinomial regression models were used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for death and FC, relative to being alive without experiencing FC, thus allowing for death as a competing risk to FC. Baseline characteristics considered for association with these joint outcomes were socio-demographic (age, sex, and level of education), economic (household income grouped into low (0--75 % of mean national income), middle (75--125 %), and high income (\>125 %), insurance status (yes or no), experience of economic hardship, and paid work status), and clinical (baseline health-related quality of life, cancer site -- separately by sex -- and cancer stage) \[[@CR21]\]. Due to small numbers for some cancer sites, sites were grouped into body location or system: digestive/gastrointestinal; breast; gynaecological; head and neck; haematological/blood; respiratory/thoracic; and other cancers. Analyses were adjusted for age, sex, cancer stage, and geographic region, grouped as low (Cambodia, Myanmar), low-middle (Indonesia, Laos, Vietnam, the Philippines), and upper-middle income (Thailand, Malaysia). Participants who experienced FC at 3 months, but could not be contacted at 12 months, were coded as having experienced FC at 12 months. Primary analyses were conducted on participants with complete data on outcome status at 12 months. More extreme cut-offs for household income groups were tested in a sensitivity analysis: low (0--50 % of mean national income); middle (50--150 %); and high income (\>150 %). Furthermore, multiple imputation (m = 5) using predictive mean matching was carried out to impute the missing data on the outcome variables. The imputation models included the outcome variables themselves, all socio-demographic, clinical, and economic predictors examined, and country \[[@CR22]\]. Analyses were performed using STATA, version 12.0 (Stata, College Station, TX, USA), and R, version 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec7}
=======

Between March 2012 and September 2013, after exclusions due to patient or doctor refusals, 9,513 patients were recruited into the study. The mean age was 52 years, 64 % were women, 61 % had attained at least secondary education, and 45 % had some form of health insurance. The most common cancer site recorded was breast (26 %); the greatest number was recruited in Indonesia (Table [1](#Tab1){ref-type="table"}). For patients with available data on cancer stage (n = 5,159), 11 % presented with stage I, 31 % with stage II, 33 % with stage III, and 24 % with stage IV cancers. Haematological cancers were diagnosed in 825 patients (Additional file [2](#MOESM2){ref-type="media"}: Table S1).Table 1Demographic, socioeconomic, and clinical characteristics of the study population (n = 9,513)Characteristicn%Age (years) \<452,78029 45--542,80130 55--642,46326 ≥651,46715 Missing2\<1Sex Male3,47037 Female6,04363Marital status Married7,35277 Not married2,15423 Missing7\<1Level of education 0--6 years (primary)3,69339 7--12 years (secondary)3,81740 \>12 years (tertiary)1,99221 Missing11\<1Country of residence Cambodia2062 Indonesia2,33525 Laos1011 Malaysia1,66218 Myanmar1,17812 Philippines90910 Thailand1,20613 Vietnam1,91620Household size 1--21,33714 3--55,55558 \>52,57027 Missing9\<1Household income (of mean national income) 0--25 %1,10312 25--50 %1,18513 50--75 %1,03111 75--100 %1,02011 100--125 %7678 125--150 %3814 150--175 %4275 175--200 %4174 \>200 %1,81919 Not known1,33614 Missing27\<1Main source of household income Crops and agricultural sidelines1,96521 Family business1,28714 Wages4,56848 Remittances and gifts4555 Other income1,21313 Missing25\<1Health insurance status Government-provided insurance3,06132 Employment-based insurance5686 Private insurance8579 Other community insurance65\<1 None5,23755 Missing11\<1Type of hospital Public8,76092 Private6106 Other (for example, military)1432Experienced economic hardship in the year before diagnosis Yes5,14654 No4,35246 Missing15\<1Paid work (patient level) before diagnosis (self-employed or for a wage) Yes4,51247 No4,99253 Missing9\<1Cancer site Mouth and pharynx1,06311 Oesophagus1602 Stomach3053 Colon and rectum91010 Liver831 Pancreas53\<1 Trachea, bronchus, and lung6237 Melanoma40\<1 Female breast2,44526 Cervix1,00511 Uterus1772 Ovary2423 Prostate47\<1 Bladder60\<1 Lymphomas and multiple myeloma4545 Leukaemia3714 Other malignant neoplasms1,29514 Missing1792Cancer stage Stage I5906 Stage II1,61317 Stage III1,69618 Stage IV1,26013 None (haematological cancers)8259 Missing3,52937

The follow-up interviews at 3 and 12 months were completed by 7,245 (76 %) and 5,245 (55 %) participants, respectively. At 12 months, 1,993 (29 %) participants had died. Complete outcome data (data on FC and death) were available for 6,787 participants (71 %) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Participant flowchart

Participants with incomplete outcome data (n = 2,726) were slightly younger (51 versus 52 years), more likely to be male (38 versus 33 %), and less likely to have a high income (17 versus 38 %), compared to those with complete outcome data (all *P* values \<0.001). There were no significant differences in other socio-demographic, clinical, or economic characteristics.

At 12 months, 3,248 participants (48 % of those with complete outcome data) experienced FC and 1,546 (23 %) were alive and did not experience FC. Survival without FC was most frequent in participants with haematological cancer (37 %), gynaecological cancer (27 %), and breast cancer (26 %) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Competing outcomes of death, financial catastrophe, and alive with no financial catastrophe at 12 months after diagnosis, by location of cancer in the body

After controlling for confounding variables, women had lower odds of death (OR, 0.62; 95 % CI, 0.51--0.75) than men, but sex was not significantly associated with FC, relative to the reference outcome (alive and no FC) (Table [2](#Tab2){ref-type="table"}). Age of \>65 years was associated with a higher odds of FC (1.51; 1.17--1.94) and death (2.64; 2.00--3.49), compared to age \<45 years. Being unmarried was also associated with a higher odds of FC (1.09; 1.09--1.60) and death (1.42; 1.15--1.77), compared to participants who were married. Having completed primary education only, compared to tertiary education, was significantly associated with a higher odds of FC (1.45; 1.16--1.82) and death (2.50; 1.93--3.25).Table 2Odds ratios (and 95 % confidence intervals) for financial catastrophe and death, relative to no financial catastrophe (reference) in all participants with complete outcome data (n = 6,787), adjusted for age, sex, cancer stage, and geographic regionCharacteristicFinancial catastropheDeathAge (years)\<45ReferenceReference45--541.05 (0.85--1.30)1.08 (0.84--1.38)55--641.41 (1.13--1.75)1.59 (1.23--2.04)≥651.51 (1.17--1.94)2.64 (2.00--3.49)SexMenReferenceReferenceWomen1.14 (0.96--1.36)0.62 (0.51--0.75)Highest level of educationTertiaryReferenceReferenceSecondary1.44 (1.16--1.79)1.43 (1.11--1.85)Primary1.45 (1.16--1.82)2.50 (1.93--3.25)Marital statusMarriedReferenceReferenceUnmarried1.32 (1.09--1.60)1.42 (1.15--1.77)Health insuranceYesReferenceReferenceNo1.27 (1.05--1.52)1.51 (1.21--1.88)Economic hardshipNoReferenceReferenceYes1.40 (1.19--1.64)1.82 (1.51--2.20)Income levelHighReferenceReferenceMiddle2.15 (1.73--2.67)1.91 (1.47--2.47)Low5.86 (4.76--7.23)5.52 (4.34--7.02)Paid workYesReferenceReferenceNo1.32 (1.11--1.56)1.60 (1.31--1.94)Cancer region: femalesDigestive/gastrointestinalReferenceReferenceBreast0.99 (0.69--1.41)0.45 (0.29--0.69)Gynaecological0.73 (0.49--1.08)0.69 (0.43--1.11)Head and neck0.69 (0.40--1.19)0.65 (0.35--1.18)Haematological/blood0.90 (0.69--1.19)1.93 (1.39--2.69)Respiratory/thoracic1.36 (0.65--2.85)2.28 (1.07--4.86)Other0.83 (0.48--1.41)0.99 (0.54--1.83)Cancer region: malesDigestive/gastrointestinalReferenceReferenceHead and neck0.54 (0.36--0.80)0.36 (0.24--0.55)Haematological/blood0.56 (0.42--0.76)1.10 (0.80--1.51)Respiratory/thoracic1.18 (0.67--2.09)1.88 (1.07--3.31)Other0.56 (0.37--0.86)0.65 (0.41--1.01)Cancer stageIReferenceReferenceII1.23 (0.94--1.60)0.93 (0.65--1.34)III1.23 (0.94--1.62)2.34 (1.65--3.33)IV1.52 (1.12--2.05)5.43 (3.77--7.82)None (haematological cancers)0.68 (0.49--0.95)3.04 (2.07--4.46)EQ-5D score (per 0.1 decrement)1.11 (1.07--1.16)1.24 (1.18--1.30)

Participants in the low income category within each country had significantly higher odds of FC (5.86; 4.76--7.23) and death (5.52; 4.34--7.02) than participants with high income, relative to being alive and no FC. Using more extreme cut-offs for low and high household income (0--50 % of the mean national income for a low income and \>150 % for a high income) resulted in higher odds of FC (9.16; 7.07--11.87) and death (9.30; 6.95--12.44) for the low income category. The country-region specific analysis showed that a low income is especially a factor in predicting FC in the upper-middle income countries (13.75; 10.21--18.51) and less so in lower-middle income countries (1.97; 1.38--2.82) (Additional file [2](#MOESM2){ref-type="media"}: Table S2a and S2b). Not having paid work also increased the odds of FC (1.32; 1.11--1.56) and death (1.60; 1.31--1.94). Having some form of health insurance provided protection from FC; those without insurance were more likely to experience FC than those with insurance (1.27; 1.05--1.52). Participants without health insurance were more likely to die (1.51; 1.21--1.88), relative to being alive and not experiencing FC; health insurance was inversely related to FC in upper-middle income countries only.

Cancer stage IV at diagnosis was significantly associated with a higher odds of FC (1.52; 1.12--2.05) and death (5.43; 3.76--7.82), compared to stage I. In terms of health-related quality of life, a decrement of 0.1 point as assessed on the EQ-5D was associated with higher odds of FC (1.11; 1.07--1.16) and death (1.24; 1.18--1.30).

In females, cancer site was not associated with FC. In males, cancer in the head and neck region (0.54; 0.36--0.80) and haematological cancers (0.56; 0.42--0.76) were associated with a lower odds of FC compared to digestive cancers (reference group).

Sensitivity analyses employing missing value imputation (Additional file [2](#MOESM2){ref-type="media"}: Table S3) did not change the inferences, except that the effect of health insurance on the odds of FC became non-significant at the conventional 5 % level.

Discussion {#Sec8}
==========

To our knowledge, the ACTION study is the largest observational study of the household burden of cancer yet conducted in Asia. A year after diagnosis, almost a third of patients affected by cancer in the ASEAN region died and almost a half of their households faced catastrophic health care expenses. Patients with advanced stages of cancer at diagnosis and socioeconomically disadvantaged cancer patients, including those with primary education only, low income, and no health insurance, were more likely to experience FC or die within 12 months.

This research adds compelling evidence to the argument for effective cancer control policies and timely access to affordable treatment in low- and middle-income countries. Previously, evidence of significant household economic burden due to cancer has come from only a few, small cross-sectional studies \[[@CR23], [@CR24]\]. There has, however, been increasing attention given to the economic impact of non-communicable diseases in low- and middle-income settings, with two recent reviews highlighting the heavy financial burden that such diseases pose on affected households \[[@CR25], [@CR26]\]. In a review of studies that reported on expenditures on chronic diseases, mean expenditures ranged from 5 % to 59 % of household income, household total health expenditure, and household non-food expenditure, but results on catastrophic health expenditures were not reported \[[@CR26]\]. A literature review on the costs imposed by non-communicable diseases in low- and middle-income settings included 19 studies that reported on OOP health expenditure as a percentage of capacity to pay or total household expenditure due to health shocks, and found that between 0 % and 34 % of the study population experienced FC, depending on the methods used \[[@CR25]\]. Comparison of these findings with our results is difficult due to differences in defining catastrophic spending: some studies used a threshold OOP share of total household expenditure; others of household 'capacity to pay'; or of 'non-food expenditure'. In addition, the threshold used also varies, ranging from 10 % to 40 %. Furthermore, in the majority of the above-mentioned studies, OOP estimates were based on retrospective recall of health care utilisation in household surveys, while our study used a prospective cost diary. Studies have shown that OOP estimates depend heavily on the measures used and length of recall periods \[[@CR27], [@CR28]\]. Compared to prospective cost diaries, health care utilisation is generally under-reported in household surveys \[[@CR27]\]. Nonetheless, results from this study, taken together with other studies, signal the potential for cancer to result in a significant economic burden.

Women were less likely to die in the year following a cancer diagnosis than men, but no significant association between the patient's sex and their household's odds of experiencing FC was found. Better survival rates for female cancers may be explained by the high proportion of breast cancer in this population, and its relatively good prognosis, while colorectal, mouth and lung cancers, with a generally poor prognosis \[[@CR29]\], were most common in men. The risk of FC increases with age, perhaps due to increasing co-morbidities which result in greater complexity of the illness and treatment. As expected, age was significantly associated with the risk of death at 12 months. A more advanced cancer stage at diagnosis was associated with higher odds of FC and death.

We found that having a below average income, no health insurance, not having paid work, having experienced economic hardship prior to diagnosis, and having experienced no more than primary education, were all associated with a higher odds of experiencing FC. Household income showed the strongest association, with these patients having more than five times the odds of FC when an income \<75 % of the mean national income was considered a low income, and even nine times the odds when an income \<50 % was used as the threshold. That this gradient was found to be more pronounced in upper-middle compared to lower-middle income countries suggests that the risk of FC posed by having a low income is as much based on relative as opposed to absolute disadvantage.

The relationship between health insurance and FC found in the primary analyses of this study was not particularly strong, and was non-significant in the sensitivity analysis where missing data were imputed. Analyses by level of economic development provided some explanation to these inconclusive results: in upper-middle income countries (Malaysia and Thailand) health insurance did provide significant protection from FC; but in lower-middle income countries it did not. This may be explained by the limitations of benefit packages available through health insurance programs in some of the participating lower-middle income countries, which has been well-recognised as a problem in Vietnam and the Philippines \[[@CR13]\]. Since health insurance status was assessed as a categorical variable it was not possible to take into account variations in level of coverage.

The findings in relation to the socioeconomic variables reinforce the well-founded conclusions that can be drawn from the social determinants literature -- those at greater levels of disadvantage tend to have higher risks of financial hardship and poor health \[[@CR30]\]. Reflecting this was the strong relationship of various socioeconomic indicators and death within 12 months. This, and the observed association between low quality of life and higher odds of FC, underscores the relationship between underlying economic disadvantage, health, and economic outcomes in cancer.

The study has a number of limitations. We did not recruit a random cross-section of people with incident cancer in the region due to a variety of reasons. First, as we could only identify cases once individuals presented to hospital, we potentially excluded individuals who did not seek hospital treatment due to geographical isolation, poverty, or socio-cultural barriers \[[@CR31]\]. Second, clinicians responsible for enrolling patients into the study appear to have under-recruited those with the most virulent types of cancer, such as lung and liver cancers. Third, public awareness of some types of cancer, specifically breast cancer, was greater than for others, which is likely to have additionally motivated certain cancer patients, particularly women, to agree to participate in the study. Furthermore, patients treated in private hospitals were under-represented in the study (6 %) and it is unclear whether this has introduced a bias in our estimates of the level of FC. Although private hospitals have often been observed to generate the highest OOP expenses \[[@CR25]\] they also tend to attract patients with a higher income. All these factors compromise the generalisability of some of our results, and probably means that we have underestimated the 12-month rate of death from all cancers, but is unlikely to invalidate the main conclusions. Another drawback is that 2,767 participants (29 %) lacked at least one component of data on death, household income, or OOP costs required to compute the study outcomes. The challenges of eliciting income and other socioeconomic data have been well-documented \[[@CR32]\], and incomplete follow-up due to being unable to contact many subjects in rural areas, despite repeated telephone calls and field visits, is inevitable in the region studied. The findings from the sensitivity analysis, in which multiple imputation was used to impute the missing data, did not vary substantially from the non-imputed findings, and would not alter conclusions.

These drawbacks have to be considered in the light of the paucity of cancer statistics from the region sampled \[[@CR2], [@CR15], [@CR33]\]. The study benefited from having a large sample of patients with various cancer sites and cancer stages from eight countries which have disparate health systems. Due to the large size of the study, it was possible to produce reliable estimates of the influence of a range of demographic, socioeconomic, and clinical predictors. In addition, the study's longitudinal approach improved on most previous economic studies which used cross-sectional surveys based on retrospective reporting of costs, as well as much smaller sample sizes, with subsequent jeopardy for both bias and sampling error. Furthermore, using a multinomial logistic regression model, we were able to adjust FC for the competing outcome of death. This is important as studies that have previously examined the burden to households associated with illnesses have generally focused exclusively on 'economic' outcomes in terms of OOP costs and FC \[[@CR10], [@CR25], [@CR26]\], but have overlooked a crucial reason why patients may avoid, or not report incurring, high OOP costs, that is, they may die, and this is unlikely to be non-informative censoring.

Conclusions {#Sec9}
===========

This study provides the type of precise evidence that is required to develop effective policies and programs to address the overall burden of cancer care in the ASEAN region, with potential generalisation elsewhere in the developing world. The results show that a cancer diagnosis is disastrous, even within only 12 months, for over 75 % of new patients. Socioeconomically disadvantaged cancer patients and patients with advanced cancer stages at diagnosis were common and particularly vulnerable to adverse economic outcomes and poor survival. The need for more resources to aid early detection as well as policies that improve access to care, by removing financial barriers and providing adequate financial protection from the costs of illness, is clear.

Key message {#Sec10}
===========

Over 75 % of new cancer patients in Southeast Asia experience financial catastrophe or die within one year. An advanced stage at diagnosis and socioeconomic disadvantage are significant risk factors for these poor outcomes. There is an urgent need for more resources to aid early detection and policies aimed to provide adequate financial protection from the costs of cancer.
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